Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelines-Reference-Cited by-同舟云学术

Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelines

Published:2020-03-23 Issue: Volume: Page:1-9
ISSN:0001-5385
Container-title:Acta Cardiologica
language:en
Short-container-title:Acta Cardiologica

Author:

Hermans Michel P.¹,Ahn Sylvie A.²,Rousseau Michel F.²

Affiliation:

1. Division of Endocrinology & Nutrition, Cliniques universitaires St-Luc and Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium;

2. Division of Cardiology, Cliniques universitaires St-Luc and Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00015385.2020.1742455

Reference22 articles.

1. Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes

2. Hermans MP, Ahn SA, Rousseau MF. Lipid disorders in diabetes. In: Tripathi K, editor. Sadikot's textbook of diabètes. New Delhi: Jaipee Brothers Medical Publishers Ltd. 2019. p. 481–495.

3. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

4. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

5. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid;European Journal of Clinical Pharmacology;2023-05-17

2. Alogliptin: a unique DPP-4 inhibitor that regulates adipose tissue insulin resistance and atherogenic lipids;2023-01-17